EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudiePragmatische StudieOpen access

Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial

Digitale Self-Management-Plattform für erwachsene Asthma-Patient:innen: randomisierte Attention-Placebo-kontrollierte Studie

Aaron Kandola iD, Kyra Edwards iD, Joris Straatman iD, Bettina Dührkoop iD, Bettina Hein iD, Joseph Hayes iD

Journal of Medical Internet Research · 2024-04-29 · 26 · e50855

DOI: 10.2196/50855 ↗

Auf einen Blick

In einer 8-wöchigen RCT verbesserte juli die Asthmakontrolle gegenüber einer App-Version mit eingeschränkter Funktionalität. Der Effekt war in der Per-Protocol-Analyse signifikant.

Fragestellung

Verbessert juli als Smartphone-Platform das Selbstmanagement und die Asthmakontrolle bei Erwachsenen mit Asthma im Vergleich zu einer Attention-Placebo-App?

Methode

Pragmatische, einblinde, randomisierte kontrollierte Studie; 1:1-Zuteilung; 8 Wochen; vollständig remote. Primär Per-Protocol, sekundär modifizierte ITT-Analyse.

Ergebnisse

411 randomisiert; 152 in der Per-Protocol-Analyse, 262 in der modifizierten ITT-Analyse. ACT nach 8 Wochen: 17,93 vs. 16,24; adjustierter Koeffizient 1,91 (95 %-KI 0,31–3,51; P=.02).

Einschränkungen

63 % Attrition zwischen Baseline und Woche 8; 63,7 % hatten die Woche-2-Bewertung abgeschlossen.

Schlussfolgerung der Autor:innen

Die Nutzung von juli war über 8 Wochen mit einer besseren Asthmakontrolle verbunden als die Nutzung einer Version mit eingeschränkter Funktionalität.

Kernaussagen

  • ACT nach 8 Wochen höher unter juli als unter Kontrolle
  • Adjustierter Koeffizient 1,91 (95 %-KI 0,31–3,51)
  • 63 % Attrition zwischen Baseline und Woche 8

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Randomisierte kontrollierte Studie in Journal of Medical Internet Research, published online on 2024-04-29. Written by Aaron Kandola and 5 co-authors. Institution: Medical Research Council Unit of Lifelong Health and Aging, University College London, London, United Kingdom. Major MEDLINE topics: Asthma, Self-Management, Mobile Applications. Cited 18 times so far (Crossref); 45 references. The full text is freely available in PubMed Central. Funded by: Wellcome Trust, Medical Research Council.

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Asthma is one of the most common chronic conditions worldwide, with a substantial individual and health care burden. Digital apps hold promise as a highly accessible, low-cost method of enhancing self-management in asthma, which is critical to effective asthma control.

Objective

We conducted a fully remote randomized controlled trial (RCT) to assess the efficacy of juli, a commercially available smartphone self-management platform for asthma.

Methods

We conducted a pragmatic single-blind, RCT of juli for asthma management. Our study included participants aged 18 years and older who self-identified as having asthma and had an Asthma Control Test (ACT) score of 19 or lower (indicating uncontrolled asthma) at the beginning of the trial. Participants were randomized (1:1 ratio) to receive juli for 8 weeks or a limited attention-placebo control version of the app. The primary outcome measure was the difference in ACT scores after 8 weeks. Secondary outcomes included remission (ACT score greater than 19), minimal clinically important difference (an improvement of 3 or more points on the ACT), worsening of asthma, and health-related quality of life. The primary analysis included participants using the app for 8 weeks (per-protocol analysis), and the secondary analysis used a modified intention-to-treat (ITT) analysis.

Results

We randomized 411 participants between May 2021 and April 2023: a total of 152 (37%) participants engaged with the app for 8 weeks and were included in the per-protocol analysis, and 262 (63.7%) participants completed the week-2 outcome assessment and were included in the modified ITT analysis. Total attrition between baseline and week 8 was 259 (63%) individuals. In the per-protocol analysis, the intervention group had a higher mean ACT score (17.93, SD 4.72) than the control group (16.24, SD 5.78) by week 8 (baseline adjusted coefficient 1.91, 95% CI 0.31-3.51; P=.02). Participants using juli had greater odds of achieving or exceeding the minimal clinically important difference at 8 weeks (adjusted odds ratio 2.38, 95% CI 1.20-4.70; P=.01). There were no between group differences in the other secondary outcomes at 8 weeks. The results from the modified ITT analyses were similar.

Conclusions

Users of juli had improved asthma symptom control over 8 weeks compared with users of a version of the app with limited functionality. These findings suggest that juli is an effective digital self-management platform that could augment existing care pathways for asthma. The retention of patients in RCTs and real-world use of digital health care apps is a major challenge. Trial Registration International Standard Randomised Controlled Trial Number (ISRCTN) registry ISRCTN87679686; https://www.isrctn.com/ISRCTN87679686

Subjects

MeSH terms (MEDLINE)

AsthmaSelf-ManagementMobile ApplicationsHumansAdultMaleFemaleMiddle AgedSingle-Blind MethodSmartphoneQuality of Life

Author keywords

RCTRCTsappapplicationapplicationsappsasthmabreathingchroniccontrolled trialcontrolled trialsdigital healthdisease managementmHealthmobile health

Authors and institutions

  • Medical Research Council Unit of Lifelong Health and Aging, University College London, London, United Kingdom.
  • juli Health, Hull, MA, United States.
  • Division of Psychiatry, University College London, London, United Kingdom.
  • Camden and Islington NHS Foundation Trust, London, United Kingdom.

ORCID profiles: Aaron Kandola, Kyra Edwards, Joris Straatman, Bettina Dührkoop, Bettina Hein, Joseph Hayes

Funding

  • Wellcome Trust
  • Medical Research Council

Cite

APA

Kandola, A., Edwards, K., Straatman, J., Dührkoop, B., Hein, B., & Hayes, J. (2024). Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial. Journal of Medical Internet Research, 26, e50855. https://doi.org/10.2196/50855

Vancouver

Kandola A, Edwards K, Straatman J, Dührkoop B, Hein B, Hayes J. Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial. Journal of Medical Internet Research. 2024;26:e50855. doi:10.2196/50855

BibTeX
@article{Kandola2024,
  author = {Kandola, Aaron and Edwards, Kyra and Straatman, Joris and Dührkoop, Bettina and Hein, Bettina and Hayes, Joseph},
  title = {Digital Self-Management Platform for Adult Asthma: Randomized Attention-Placebo Controlled Trial},
  journal = {Journal of Medical Internet Research},
  year = {2024},
  volume = {26},
  pages = {e50855},
  doi = {10.2196/50855}
}
Start for free →